This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

All News

All news

  • News Troubleshooting from a tablet manufacturer’s perspective

    I Holland to host a solutions-led seminar focusing on resolving tablet compression issues.
  • News Rentschler Biotechnologie transitions into a European corporation called Rentschler Biopharma SE

    This legal form of company strengthens its position as a full-service CDMO and ensures its place as an industry leader.
  • News Boosting capabilities through collaboration

    CDMO, Micro-Sphere partners with German machine manufacturer Harro Höfliger for the latest step in its 21 million CHF (€19 million) investment into its facility in Switzerland.
  • News OMYA Partners with LODAAT for Distribution

    Leading Swiss Distributor, OMYA, partners with LODAAT for distribution of LODAAT Premium botanical molecules in USA market.  OMYA will distribute select products and add LODAAT's premium pharma-grade ingredients to its current product line.
  • News Merck invests €35 million in its Italian biotech manufacturing site of Bari

    New production line for the aseptic filling of biotech medicines under isolator.

    Jordan Sweden Medical and Sterilization Company (JOSWE® Medical) is still committed to its mission: to improve people’s health by developing and providing high quality branded first generic medicines at affordable prices.
    We delivered...
  • News Tubilux selects TraceLink to achieve EU FMD Compliance

    By leveraging TraceLink’s network tenant architecture, Tubilux can eliminate the complexity and costs associated with point-to-point integrations for its EU pharmaceutical manufacturing customers.
  • News Construction starts for Sartorius' new Cell Culture Technology Centre

    The 30-million-euro investment will accommodate the growing needs of customers.
  • News PnuVax awarded $29.4 million grant to advance innovative vaccine into clinical trials

    Use of PnuVax’s unique patented conjugation platform technology to produce the vaccine is expected to speed up biomanufacturing and increase yield for a greatly reduced per-dose cost.
  • News SGS partnership helps clients to beat pharmaceutical counterfeiting

    Partnership will provide SGS clients with a unique additional analytical service that uses cutting-edge technology to verify product authenticity, process authenticity and product/process infringement.
  • News Brammer Bio expands "much needed" cell and gene therapy capacity

    CDMO partners with Pall Life Sciences to deliver an end-to-end single-use platform solution from upstream to downstream.
  • News Quanticate doubles its footprint in India

    New center of excellence to support further development of collaborative, long-term partnerships with leading pharmaceutical companies.
  • News Domestic companies predict a 16% growth in the South Korean pharma market

    CPHI onsite survey highlights emerging trends in 2017 for South Korean pharma.
  • News Highly potent APIs - can your CMO handle them?

    The importance of ensuring a facility has the right capabilities when selecting a CMO to handle high potency ingredients.
  • News CPHI Worldwide Pharma Awards finalists unveiled

    Largest ever CPHI Pharma Awards receives 200+ entries, with judges evaluating over 250,000 words.
  • News RisdropTM Launch

    Berry Global announces the launch of RisdropTM, an innovative, user independent eye dropper with a unique nozzle technology.
    RisdropTM design has excellent flow control with low drop size variance, delivering one reliable and consistent d...
  • News Ardena acquisition will support sponsors with bioanalytical and drug discovery services

    CDMO on target to become a one-source contract partner for early-phase development.
  • News Centauri scoops up to £945K award to develop innovative antibiotics

    Project will use the company's Alphamer technology, which is based on 'programmable immunity' in which chemically synthesized molecules redirect naturally occurring antibodies to selected pathogens to fight the infection.
  • News Lyophilization questions answered in real time

    Two free webinars - 'Lyophilizer Sublimation and Heat Transfer Modelling' and 'The Freezing Stage in Freeze Drying: Fundamental Concepts 2.0' - delivered by industry experts.
  • News Won the first position in Food and Agro products category in India for highest export

    Won the first position in Food and Agro products category in India for highest export for 2014-2015 under export excellence awards.
    It was awarded by Smt. Nirmala Sitharaman - honorable Commerce Minister.
  • News LODAAT Awarded BEST Pharma EXPORTER State of Illinois 2016

    Lodaat was awarded Best Exporter from the Illinois Governor's Office for 2nd year.  This prestigious honor was awarded because of Lodaat's export volume, and reputation
  • News Emulsifying, encapsulating and eliminating in one go

    Ear health and hygiene with a novel twist.
  • News MTHP : 4-Methyltetrahydropyran, A new hydrophobic solvent

    CARLO ERBA Reagents is pleased to offer a new versatile solvent : 4-Methyltetrahydropyran (MTHP).
    This new hydrophobic cyclic ether is an excellent substitute to THF or 2-Methyl THF in various applications (Grignard reactions, LAH reduction, cross...
  • News Building on shaky foundations? 'No way' says Sartorius

    Award-winning building protected by special construction against vibration and temperature fluctuations.

    The European Commission has recently announced the approval of the PREMIUM proposal: “Preservation of microorganisms by understanding the protective mechanisms of oligosaccharides”, submitted to the call: H2020-MSCA-RISE-2017.

    The Marie Sklo...

    Nitika had  started  Additional site of  production. Since our Old site of production is Under Renovation. We Started our commercial production for the products mentioned in FDA license R...
  • News New service delivers streamlined pathway for Phase I trial milestones

    Whether you're a small, virtual firm or Big Pharma, Recipharm Pathway to Clinic can remove the complexity out of first in human projects.
  • News Recipharm and CTC launch integrated first in human service

    Contract development and manufacturing organisation (CDMO) Recipharm and contract research organisation (CRO) Clinical Trial Consultants (CTC) have partnered to launch a new service that delivers a clear, streamlined pathway to first in human milestone...
  • News Opdivo + Yervoy combination demonstrated superior overall survival in patients with kidney cancer

    The combination therapy reduced the risk of death by 37% versus standard of care, sunitinib, in intermediate- and poor-risk patients.
  • News FDA warns Pfizer company about cGMP violations associated with the manufacture of EpiPen

    Warning letter cites Meridian Medical Technologies' failure to thoroughly investigate multiple serious component and product failures of EpiPen products.
  • News Monthly migraine days significantly reduced with erenumab

    The drug is the first and only fully human monoclonal antibody of its kind, uniquely designed to specifically block the CGRP receptor, which plays a critical role in activation of migraine.
  • News Research reveals costly implementation is the biggest barrier to serialization compliance

    The time it takes to develop a solution has been gravely underestimated by a large part of the industry.
  • News Merck prepares strategic options for the Consumer Health business

    Important step in executing science and technology focused strategy.
  • News Novo Nordisk settles US federal investigation of marketing practices

    In connection with the $60 million settlement, the company has also resolved several private whistle-blower cases related to the government's investigation.
  • News Eli Lilly streamline operation to affect 3500 workers

    Majority of the positions eliminated expected to come from a US voluntary early retirement program.
  • News Vectura and Pulmatrix sign branded generic tiotropium bromide development agreement

    Major new tiotropium bromide DPI development programme accelerated through licensing of Pulmatrix technology.
  • News FarmacistaPiù: The Diabetic Corner wins the #NextPharmacy Contest

    "The Diabetic Corner” wins the best project in the category “Innovation in the pharmacy with the patient at centre stage” at  FarmacistaPiù event, staged in Milan on 8-10 May 2015.

  • News Cosmofarma: Pharmacy Management Award

    Cosmofarma, the leading pharmacy world event in Europe, rewards the Harmonium Pharma project as part of the Innovation & Research Award, in the category “Pharmacy management”.

  • News Innovation Harmonium S.L. - New company in the Technology Park in Gran Canaria

    The headquarters of Harmonium Innovation, the research and development company of the Harmonium Group, will be incorporated in the prestigious “Technology Park in Gran Canaria”.
  • News Diabetic Foot: a unique project in terms of prevention

    A complete path to accompany people with diabetes from early screening to prevention and care of Diabetic Foot
  • News Colipex: results of clinical study presented in Stockholm

    Good news for diabetic people comes from a study conducted by Dr. Andrea Scaramuzza of the Luigi Sacco Hospital (Milan), the results of which were presented at the 51st EASD (European Association for the Study of Diabetes) Congress in Stockholm.
  • News Life-extending pancreatic cancer medicine recommended by NICE in final guidance

    The pivotal Phase III study demonstrated that treatment with Abraxane in combination with gemcitabine can offer patients a median overall survival improvement of 1.8 months.
  • News Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in immuno-oncology

    Rigontec’s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements Merck's strategy and current pipeline.
  • News Landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

    PARADIGMS is a first of its kind study in pediatric MS. Other current treatments have not been evaluated in head to head trials specifically designed for children and adolescents.
  • News The Wasdell Group to Launch QP Services at CPhl in Frankfurt in October 2017

    After another successful year which saw the Wasdell Group add Contract Manufacturing to its already well established outsourcing services, the UK based Wasdell Group will be launching their QP Services capabilities at CPHI in Frankfurt in October.
  • News Novartis CEO, Joseph Jimenez, to retire from Novartis in 2018

    Vasant Narasimhan appointed CEO, effective 1February 2018.
  • News SGS Clinical Research strengthens its consultancy service to accelerate drugs through early phase development

    Company consolidates its consultancy portfolio into a single, comprehensive offering.
  • News Catalent signs commercial manufacturing agreement with US WorldMeds for lofexidine

    Lofexidine is an investigational drug under development to mitigate symptoms associated with opioid withdrawal.
  • News Clintec expands UK headquarters and is presented with Queens Award for Enterprise – International Trade

    Company's additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters forms a fully dedicated centre of excellence for clinical research and quality assurance capabilities.
  • News Takeda disappointed as NICE issue second negative draft decision for ixazomib

    Company says it is determined to work collaboratively to find a solution.
  • News Prevent Lyme diseases – innovative tick solution!

    Global emerging problem and new preventive solutions against tick-borne diseases from ICB Pharma- KICK THE TICK® expert.
  • News Janssen enters exclusive distribution agreement for Invokana and Vokanamet

    Distribution agreement covers countries in the EEA and Switzerland.
  • News Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly

    Midatech on track to start clinical development with MTD201 in Q4 2017.
  • News 3SBio accelerates expansion of its global biologics platform

    The Chinese biopharmaceutical company acquires the Canadian biomanufacturing business of Therapure.
  • News Bayer submits BLA in the for BAY94-9027 – a long-acting factor VIII for the treatment of hemophilia A

    Pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals.
  • News Merck successfully closes biosimilars transaction

    Step towards strategic alignment of R&D resources to Healthcare priorities.
  • News FDA approves Pfizer's Mylotarg for treatment of AML

    Only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive AML.
  • News H&T Presspart and Hovione Technology Enter Dry Powder Inhalation Partnership

    H&T Presspart, the world’s leading manufacturer of components for metered dose inhalers (MDIs), today announced a collaborative partnership with Hovione Technology, supporting a strategic plan to expand its portfolio of novel drug delivery systems...
  • News Xeno-free cell culture medium for regenerative medicine research

    StemFit Basic02 offers superior and stable growth performance, high colony forming efficiency and robust scalable cell expansion.
  • News Thermo Fisher Scientific completes acquisition of Patheon

    Patheon's CDMO capabilities coupled with Thermo's clinical trials services and bioproduction technologies expected to make Thermo and "even stronger partner" for its pharmaceutical and biotech customers.
  • News AstraZeneca and Takeda collaborate to develop and commercialise MEDI1341 for Parkinson’s disease

    MEDI1341 has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies.
  • News Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

    ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.

    • Unique Offer
    • Highest Quality Standards
    • Guaranteed Traceability
    • Expertise at your Service
    • Reliable Partner
  • News Cambrex invests in new analytical development and method validation laboratory at its High Point, NC Facility

    Expansion comes as a result of increased industry demand to better understand and characterize APIs and process intermediates at the clinical stage.
  • News Lilly to file baricitinib resubmission to FDA before end of January 2018

    Resubmission package will include new safety and efficacy data.
  • News Novartis receives first ever FDA approval for a CAR-T cell therapy

    Kymriah approvaed for children and young adults with B-cell ALL that is refractory or has relapsed at least twice.
  • News FDA approves new antibacterial drug

    First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor.
  • News Fire at Ashland facility suspends production of BDO, THF and formaldehyde

    Volume expected to remain somewhat constrained into the first quarter of fiscal 2018.
  • News Krystal microplate enables development of drug testing assay

    Scientists at the NCBS using Krystal 384-well black microplates to produce a standard drug testing assay for Plasmodium vivax infection.
  • News New Offices in China, Japan and the United Kingdom.

    We have recently opened Offices in China, Japan and the United Kingdom. We have full time Employees in the Overseas Offices. New products are under developments for various applications.
  • News Berg and AstraZeneca collaborate to identify new therapeutic targets to treat neurological disorders

    Collaboration to focus on a disease target in Parkinson's disease with Berg's Interrogative Biology technology.
  • News New Repatha data support lower LDL-C levels for high-risk cardiovascular patients

    No evidence of a leveling off of effect and no new safety concerns were identified in this analysis.
  • News Sanofi completes the acquisition of Protein Sciences

    An innovative quadrivalent influenza vaccine will complement Sanofi Pasteur vaccine portfolio.
  • News Biogen’s adalimumab biosimilar referencing Humira, is approved in the EU

    Biogen becomes the first company with approved biosimilars for the three most prescribed anti-TNF biologic treatments in Europe.
  • News Class action lawsuit filed on behalf of investors in Teva

    Complaint alleges Teva failed to disclose the poor performance of its US generics business and the subsequent goodwill impairment charge stemming from the company’s purchase of Actavis Generics.
  • News Boehringer Ingelheim receives FDA approval for its Humira biosimilar

    Cyltezo approved for the treatment of multiple chronic inflammatory diseases.
  • News Regeneron and Sanofi to present new analyses from Praluent injection trials

    Presentations include results from ODYSSEY APPRISE, an open-label study in 16 European countries and Canada in patients with severe hypercholesterolemia at high cardiovascular risk.
  • News EC approves first oral short-course treatment for highly active relapsing multiple sclerosis

    Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years.
  • News MedPharm strengthens management on back of US success

    Appointments come as global leader in contract topical and transdermal pharmaceutical development benefits from increased revenues.
  • News Otsuka and Mylan sign license agreement to commercialize delamanid for MDR-TB in high-burden countries

    Mylan granted an exclusive license by Otsuka to prioritize access to Deltyba in South Africa and India.
  • News FDA grants Priority Review to Genentech's emicizumab for Hemophilia A with inhibitors

    Application based on positive results of Phase III study in adults and adolescents with hemophilia A with inhibitors and interim Phase III results in children.
  • News Charles River Laboratories acquires Brains On-Line

    Establishes Charles River as a premier source for CNS contract research services.
  • News Novavax’ preclinical influenza nanoparticle study published in Vaccine

    Data suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults.
  • News Novartis and MMV launch patient trial in Africa for a novel compound against multidrug-resistant malaria

    Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.
  • News Bavarian Nordic closes transaction with Janssen Pharmaceuticals

    Collaboration grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two additional programs, targeting vaccines against hepatitis B virus and the human immunodeficiency virus.
  • News Amgen and Humana partner for improved health outcomes and efficiency

    Partnership to target multiple serious diseases using real world data studies.
  • News Spray drying specialist to invest €19 million in GMP facility expansion

    Investment is in response to increased market for spray drying and capsule filling for dry powder inhalers.
  • News Oak Therapeutics completes critical milestone in Phase I to develop oral dissolvable strip for TB

    Comapny has created a novel formulation to produce a product prototype containing 300 mg of Isoniazid, that is both rapidly dissolving and mucoadhesive.
  • News Oxford Genetics secures £7.5 million investment

    Investment will fund a new office in Boston, US, an extension of its UK facility at the Oxford Science Park, and R&D capabilities to increase its intellectual property portfolio.
  • News Champions Oncology collaborates with AstraZeneca to develop unique cohorts of PDX models

    Models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer.
  • News RedHill Biopharma announces US commercialization agreement for FDA-approved GI product

    Esomeprazole Strontium DR capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor, indicated for adults for the treatment of gastroesophageal reflux disease and other gastrointestinal conditions.
  • News BMS and Pfizer to highlight commitment to reducing the risk of stroke at ECS Congress 2017

    Eliquis clinical data include results from a Phase IV trial to be featured in late-breaking science sessions,
  • News A plant-based delivery system for anti-cancer drugs

    Study demonstrates that a complex consisting of tobacco mosaic virus and vcMMAE can kill cancer cells.

    Glatt Pharmaceutical Services, the CDMO division of Glatt offers its formulation and product development services using innovative direct pelletizing technologies to support you with tailored solutions. Some of the Technologies are described below.
  • News Hikma statement on generic Advair Diskus

    Company been able to clarify and resolve a number of the questions raised by the FDA.
  • News Mylan finalizes settlement agreement on Medicaid rebate classification for EpiPen Auto-Injector

    Mylan will reclassify EpiPen Auto-Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products effective as of 1 April 2017.
  • News Pfizer to adopt Orion cloud platform for computational chemistry

    Orion's workflow tools will help Pfizer's efforts to deliver potential breakthrough therapies for patients.
  • News Hikma announces new licensing agreement with Takeda for products in the MENA

    Hikma granted the exclusive rights to manufacture and commercialise three of Takeda’s leading primary care product families.
  • News Serialization software for FMD compliance

    This month in Pharmaceutical Manufacturing and Packing Sourcer, Verify Brand’s CEO, Michael Howe, addresses how Europe’s Falsified Medicines Directive (FMD) not only provides health and safety benefits to patients, it also presents an opportunity ...
  • News Evotec completes acquisition of Aptuit

    Employees and capabilities will be integrated into Evotec's global drug discovery group to maximise commercial synergies.
  • News Vectura signs global development agreement with Dynavax

    Agreement convers the clinical application of Vectura's proprietary smart nebuliser technology to deliver Dynavax's investigational immunotherapeutic agent to lung cancer patients.
  • News Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity

    Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.
  • News Abcam and TTP Labtech collaborate to develop sol-R reagent kits

    Assay-ready kits will incorporate fully-validated, industry-leading recombinant antibody technology for high throughput research.
  • News The Great Hall of China: double digit growth at CPHI China

    The Asian pharma event surpasses 55,000 visits with more than 10,000 overseas visits.
  • News Bespoke filtration equipment enables pharma manufacturer to fulfil contract

    Major pharma manufacturer delivers critical drugs to a leading children's hospital.
  • News Cambridge Epigenetix and NuGEN Technologies combine leading technologies in epigenetics research

    Co-exclusive global licence covers manufacture and integration of CEGX TrueMethyl technology for oxidative bisulfite sequencing with Targeted Methylation and NuGEN Ovation Methyl-Seq systems.
  • News Shire submits lifitegrast MAA for treatment of dry eye disease in Europe

    Lifitegrast, if approved, would be the first and only new class treatment to address the signs and symptoms of dry eye disease in adults in Europe.
  • News Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline

    Inotersen on track for marketing authorization filings this year.
  • News Fortress Biotech forms new subsidiary, Aevitas Therapeutics

    Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.
  • News Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

    The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.